FDA outlines steps for individualized drug development

被引：0
|
作者：
Asher Mullard
机构：
来源：
Nature Reviews Drug Discovery | 2021年 / 20卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：91 / 91
相关论文
共 50 条
  • [41] FDA Initiative to Address Gaps in Analgesic Drug Development
    Boughton, Barbara
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2011, 4 (01): : 3 - 3
  • [42] FDA Patient-Focused Drug Development Guidances
    Berg, Anne T.
    Ludwig, Natasha N.
    Wojnaroski, Mary
    Chapman, Chere A. T.
    Hommer, Rebecca
    Conecker, Gabrielle
    Hecker, JayEtta Z.
    Downs, Jenny
    NEUROLOGY, 2024, 102 (01)
  • [43] Biomarkers, Drug Development, and Pathways for FDA Consideration.
    Mattes, W. B.
    ENVIRONMENTAL AND MOLECULAR MUTAGENESIS, 2016, 57 : S54 - S54
  • [44] TOWARDS THE DEVELOPMENT OF A STRATEGY FOR INDIVIDUALIZED DRUG-THERAPY IN SCHIZOPHRENIA
    AWAD, AG
    HOGAN, TP
    HOSPITAL FORMULARY, 1987, 22 (05): : 480 - +
  • [45] FDA Outlines Proposed Ban on Menthol Cigarettes, Flavored Cigars
    Stephenson, Joan
    JAMA HEALTH FORUM, 2022, 3 (05): : e221664
  • [46] Six Steps to Improve FDA Enforcement
    Haniff, Haydia
    BIOPHARM INTERNATIONAL, 2009, 22 (09) : 12 - 12
  • [47] FDA user fee renewal addresses drug shortages, new drug development
    Wechsler, Jill
    FORMULARY, 2012, 47 (03) : 125 - 126
  • [48] A Comparison of FDA and EMA Drug Approval: Implications for Drug Development and Cost of Care
    Howie, Lynn J.
    Hirsch, Bradford R.
    Abernethy, Amy P.
    ONCOLOGY-NEW YORK, 2013, 27 (12): : 1195 - +
  • [49] FDA: Early stage drug development costs trigger higher drug costs
    2018, UBM Medica Periodical Publication (42)
  • [50] FDA's Hamburg steps down
    Nature Biotechnology, 2015, 33 (3) : 218 - 218
12345